Amendments to the Claims

Claims 1-4, 8-11, 13-17, 21-23, and 25 are pending in the application. Claims 1 and 14 have been amended to add the element that the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups. The amendment is supported in the specification on page 8, lines 22-24. Please amend claims 1 and 14 as follows:

1. (currently amended) A hydrogel wound dressing formed by spray delivery of a liquid composition to the wound, wherein the composition comprises water soluble PVA macromers having one or more pendant crosslinkable groups and the macromers crosslink to form a hydrogel *in situ* on the wound, wherein the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups.

14. (currently amended) A method of forming a hydrogel wound dressing, comprising the step of applying a composition to a wound via spray, wherein the composition comprises water soluble PVA macromers having one or more pendant crosslinkable groups and the macromers crosslink to form a hydrogel on the wound, wherein the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups.

Listing of Claims

1. (currently amended) A hydrogel wound dressing formed by spray delivery of a liquid composition to the wound, wherein the composition comprises water soluble PVA macromers having one or more pendant crosslinkable groups and the macromers crosslink to form a hydrogel *in situ* on the wound, wherein the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups.

2. (original) The wound dressing of claim 1, wherein the hydrogel is degradable.

3. (original) The wound dressing of claim 1, wherein the composition is delivered via an aerosol delivery device.

4. (original) The wound dressing of claim 1, wherein the composition is delivered via a pump spray delivery device.

5-7. (cancelled)

8. (original) The wound dressing of claim 1, wherein the composition further contains one or more additives selected from the group consisting of preservatives, biologically active agents, defoamers, wettings agents, leveling agents, hydrating agents, thickeners, fillers, and absorbents.

9. (previously presented) The wound dressing of claim 8, wherein the active agent is selected from the group consisting of growth factors, nitric oxide, antibiotics, anti-inflammatories, analgesics, blood coagulants, and enzymes.

10. (original) The wound dressing of claim 8, wherein the active agent is one which delivers NO to the wound.

11. (original) The wound dressing of claim 1, wherein the dressing debrides the wound when it is removed.

12. (cancelled)

13. (previously presented) The wound dressing of claim 1, wherein the *in situ* crosslinking is in response to redox initiation.

14. (currently amended) A method of forming a hydrogel wound dressing, comprising the step of applying a composition to a wound via spray, wherein the composition comprises water soluble PVA macromers having one or more pendant crosslinkable groups and

the macromers crosslink to form a hydrogel on the wound, wherein the pendant crosslinkable groups are acrylamide groups containing olefinically unsaturated groups.

15. (original) The method of claim 14, wherein the hydrogel is degradable.

16. (original) The method of claim 14, wherein the composition is delivered via an aerosol delivery device.

17. (original) The method of claim 14, wherein the composition is delivered via a pump spray delivery device.

18- 20. (cancelled)

21. (original) The method of claim 14, wherein the composition further contains one or more additives selected from the group consisting of preservatives, biologically active agents, defoamers, wettings agents, leveling agents, hydrating agents, thickeners, fillers, and absorbents.

22. (previously presented) The method of claim 21, wherein the active agent is selected from the group consisting of growth factors, nitric oxide, antibiotics, anti-inflammatories, analgesics, blood coagulants, and enzymes.

23. (original) The method of claim 21, wherein the active agent is one which delivers NO.

24. (cancelled)

25. (previously presented) The method of claim 14, wherein the *in situ* crosslinking is in response to redox initiation.

26. (cancelled)

Conclusion

Reconsideration of the claims as amended is respectfully requested.

Respectfully submitted,

Collen A. Beard
Registration No. 38,824

Law Office of Collen A. Beard, LLC
P.O. Box 1064
Decatur, Georgia 30031-1064
(404).373.5065

Certificate of Transmission Under 37 C.F.R. §1.8(a)

I hereby certify that this paper, along with any paper referred to as being enclosed or attached, is being transmitted by facsimile to the United States Patent and Trademark Office or is deposited with the U.S. Postal Service with sufficient postage as first class mail to the facsimile number or address shown above.

Collen A. Beard

Date: February 19, 2004